4-Allyl-5-allyloxymethyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester | 288584-34-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 4-Allyl-5-allyloxymethyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 2,2-dimethyl-5-(prop-2-enoxymethyl)-4-prop-2-enyl-1,3-oxazolidine-3-carboxylate
• CAS: 288584-34-9
• 化学式: C₁₇H₂₉NO₄
• 分子量: 311.422
• InChiKey: FKSRMUGQMHIBQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  48
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Protease inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US20020165222A1

  公开（公告）日：2002-11-07

  The present invention provides 7-14 membered ring ether protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

  本发明提供了7-14元环醚蛋白酶抑制剂及其药物可接受的盐，水合物和溶剂化物，其可抑制蛋白酶，包括卡他蛋白K，以及这些化合物的制药组合物，这些化合物的新中间体，以及治疗过度骨质流失或软骨或基质降解等疾病的方法，包括骨质疏松症；牙龈疾病，包括牙龈炎和牙周炎；关节炎，更具体地说是骨关节炎和类风湿性关节炎；帕吉特病；恶性高钙血症；和代谢性骨病，通过向需要的患者投与本发明化合物来抑制骨质流失或过度软骨或基质降解。
• EP1153022A4
  申请人：——

  公开号：EP1153022A4

  公开（公告）日：2002-03-27
• PROTHEASE INHIBITORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1153022A1

  公开（公告）日：2001-11-14
• [EN] PROTHEASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTEASE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2000049011A1

  公开（公告）日：2000-08-24

  The present invention provides 7-14 membered ring ether protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.